Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $142

Citigroup analyst Samantha Semenkow maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $131 to $142.